ReviewGM crops & food2025
To patent or not to patent: challenges and solutions to the patent ban on new genomic techniques plant in EU.
Review in GM crops & food, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Proposal for a new Regulation on plants produced by certain new genomic techniques (NGTs) embraces the deregulation of NGT plants but introduces a patent ban on them. This move has generated significant legal uncertainties and has become the focal point of a broader debate over the patentability of NGT plants. In reviewing the rationale and challenges underlying the patent ban, this article argues that the abandonment of patents diverges from established expectations. Introducing a new complete patent ban is likely to lead to several adverse consequences, including challenges related to justification, implementation, and innovation. Instead of radically altering the NGT plant patent framework, more practical and balanced alternatives within existing patent system - such as the establishment of a patent-clearing platform, the adoption of a compulsory licensing model and the creation of a labeling and traceability system - may offer more effective solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.